US5424331A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
Assignee: ACDS TECHNOLOGIES Inc
•
Filing: 1994-06-10
•
Granted: 1995-06-13
•
Expires: 2014-06-10
Abstract
Abstract A composition for the treatment or prevention of osteoporosis, is disclosed, which comprises: (a) 75 to 200 parts of one or more phytoestrogen compounds; (b) 0 to 100 parts of dried licorice root extract; (c) 300 to 600 parts of calcium contained in a biologically acceptable calcium salt; (d) 70 to 280 parts of magnesium contained in a biologically acceptable magnesium salt; (e) 4 to 25 parts of zinc contained in a biologically acceptable zinc salt; (f) 5 to 20 parts of beta-carotene; (g) 0.005 to 0.010 parts of Vitamin D as cholecalciferol; and (h) 6 to 12 parts of Vitamin E, in admixture with a biologically acceptable inert carrier. The new compositions are administered to a mammalian subject as either a pharmaceutical or as a dietary supplement.
Inventors
- 👤 Mark Shlyankevich
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 23:55
CPC Classifications
A; A61; A61K; A61K36/00; A61K36/18; A61K36/185; A61K36/23; A61K36/236
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
137 words
A composition for the treatment or prevention of osteoporosis which comprises: (a) 75 to 200 parts of one or more phytoestrogen compounds, wherein the phytoestrogen compound is a coumestan or an isoflavone selected from the group consisting of daidzein, genistein, glycitein, daidzin, genistin, glycitin, an acetylated form thereof and mixtures thereof; (b) 0 to 100 parts of dried licorice root extract; (c) 300 to 600 parts of calcium contained in a biologically acceptable calcium salt; (d) 70 to 280 parts of magnesium contained in a biologically acceptable magnesium salt; (e) 4 to 25 parts of zinc contained in a biologically acceptable zinc salt; (f) 5 to 20 parts of beta-carotene; (g) 0.005 to 0.010 parts of Vitamin D as cholecalciferol; and (h) 6 to 12 parts of Vitamin E, in admixture with a biologically acceptable inert carrier.
Claim 2
Dependent Claim
137 words
A composition for the treatment or prevention of osteoporosis which comprises: (a) 75 to 200 parts of one or more phytoestrogen compounds, wherein the phytoestrogen compound is a coumestan or an isoflavone selected from the group consisting of daidzein, genistein, glycitein, daidzin, genistin, glycitin, an acetylated form thereof and mixtures thereof; (b) 0 to 100 parts of dried licorice root extract; (c) 300 to 600 parts of calcium contained in a biologically acceptable calcium salt; (d) 70 to 280 parts of magnesium contained in a biologically acceptable magnesium salt; (e) 4 to 25 parts of zinc contained in a biologically acceptable zinc salt; (f) 5 to 20 parts of beta-carotene; (g) 0.005 to 0.010 parts of Vitamin D as cholecalciferol; and (h) 6 to 12 parts of Vitamin E, in admixture with a biologically acceptable inert carrier.
Claim 3
Dependent Claim
20 words
The composition for the treatment or prevention of osteoporosis defined in claim 1 wherein the phytoestrogen compound is a coumestan.
Claim 4
Dependent Claim
50 words
The composition for the treatment or prevention of osteoporosis defined in claim 1 wherein the mixture of isoflavones includes: 120 to 180 parts by weight of daidzin; 280 to 350 parts of genistin; 80 to 120 parts by weight of daidzein; and 8 to 12 parts by weight of genistein,
Claim 5
Dependent Claim
18 words
The composition for the treatment or prevention of osteoporosis defined in claim 2 wherein the coumestan is coumestrol.
Claim 6
Dependent Claim
36 words
A method of treating or preventing osteoporosis in a mammalian subject which comprises the step of administering to said subject an amount of the composition defined in claim 1 effective to treat or to prevent osteoporosis.
Claim 7
Dependent Claim
21 words
The method of treating or preventing osteoporosis defined in claim 5 wherein the composition is orally administered to the mammalian subject.
Claim 8
Dependent Claim
26 words
The method of treating or preventing osteoporosis defined in claim 5 wherein the mammalian subject to which the composition is administered is a post-menopausal female subject.
Claim 9
Dependent Claim
28 words
The method of treating or preventing osteoporosis defined in claim 6 wherein the composition is a dietary supplement administered to the mammalian subject as a tablet or capsule.
Claim 10
Dependent Claim
23 words
The method of treating or preventing osteoporosis defined in claim 6 wherein the composition is a dietary supplement admixed with the subject's food.
Claim 11
Dependent Claim
86 words
A composition for the treatment or prevention of osteoporosis which comprises: (a) 75 parts by weight of genistin; (b) 50 parts by weight of dried licorice root extract; (c) 750 parts by weight of calcium carbonate; (d) 160 parts by weight of magnesium oxide; (e) 15 parts by weight of zinc sulfate; (f) 5 parts by weight of beta-carotene; (g) 0.005 parts by weight of Vitamin D as cholecalciferol; and (h) 6 parts by weight of Vitamin E; in combination with a biologically acceptable inert carrier.
Claim 12
Dependent Claim
86 words
A composition for the treatment or prevention of osteoporosis which comprises: (a) 75 parts by weight of genistin; (b) 50 parts by weight of dried licorice root extract; (c) 750 parts by weight of calcium carbonate; (d) 160 parts by weight of magnesium oxide; (e) 15 parts by weight of zinc sulfate; (f) 5 parts by weight of beta-carotene; (g) 0.005 parts by weight of Vitamin D as cholecalciferol; and (h) 6 parts by weight of Vitamin E; in combination with a biologically acceptable inert carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-06-12 | 1998-12-12 | 1999-06-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-06-12 | 2002-12-12 | 2003-06-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-06-12 | 2006-12-12 | 2007-06-13 | $7700.00 | Window Closed / Lapsed |